Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Impact of antibiotic use on checkpoint inhibitor efficacy

Jared Weiss • 3 Jun 2020
ASCO 2020
General Checkpoint Inhibitors

Jared Weiss, MD, of UNC Lineberger, Chapel Hill, NC, explores the impact of antibiotic use on the efficacy of checkpoint inhibitor therapies based on changes in the gut microbiome. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Jared Weiss

1:05
Revisiting farnesyltransferase inhibitors for head and neck cancer
Jared Weiss • 3 Jun 2020
3:05
ASCO 2020: head and neck cancer highlights
Jared Weiss • 3 Jun 2020
4:22
Myelopreservation and reduced use of supportive care with trilaciclib in patients with SCLC
Jared Weiss • 3 Jun 2020
4:24
Reflections on the ADAURA study
Jared Weiss • 3 Jun 2020

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals